PMID- 25809314 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20150326 LR - 20220409 IS - 2155-384X (Print) IS - 2155-384X (Electronic) IS - 2155-384X (Linking) VI - 6 IP - 3 DP - 2015 Mar 26 TI - Topical Steroid Therapy for the Treatment of Eosinophilic Esophagitis (EoE): A Systematic Review and Meta-Analysis. PG - e82 LID - 10.1038/ctg.2015.9 [doi] AB - OBJECTIVES: Current guidelines recommend topical steroids as first-line treatment for patients with eosinophilic esophagitis (EoE). However, the evidence for this approach has been inconsistent in earlier reports. This meta-analysis aimed to clarify the efficacy of topical steroid treatment in active EoE using updated evidence. METHODS: CENTRAL, MEDLINE and EMBASE databases were searched for randomized controlled trials (RCTs) published up to May 2014 that compared topical steroids with control treatments for active EoE. Study bias was assessed using the Cochrane Collaboration Tool, and outcomes were pooled using random effects models. The primary outcome was the mean change in eosinophil counts. Secondary outcomes were symptom responses and adverse events. RESULTS: In total, seven RCTs (226 patients) were included. Topical steroids were associated with a significant reduction in esophageal mucosal eosinophil counts compared with control therapy although substantial heterogeneity between studies was observed (weighted mean difference (WMD) -27.2, 95% confidence interval (CI) -45.3 to -9.1, I(2)=56.2%). Subgroup analysis indicated the reduction in eosinophil counts was only present in studies where a proton pump inhibitor (PPI) trial was used to exclude other diagnoses (WMD -46.3, 95% CI -61.3 to -31.4, I(2)=0.0%). Subdivision of studies on the use of a PPI trial also accounted for the majority of heterogeneity among RCTs. No clear trends in symptom resolution were observed. Eleven out of 127 patients who received topical steroids developed asymptomatic esophageal candidiasis. CONCLUSIONS: These data provide updated high-quality evidence that support current guidelines for first-line EoE treatment with topical steroids after an initial PPI trial to exclude non-EoE pathologies (PROSPERO ID: CRD42014008828). FAU - Chuang, Ming-Yu Anthony AU - Chuang MY AD - Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia. FAU - Chinnaratha, Mohamed A AU - Chinnaratha MA AD - School of Medicine, Flinders University, Bedford Park, South Australia, Australia. FAU - Hancock, David G AU - Hancock DG AD - School of Medicine, Flinders University, Bedford Park, South Australia, Australia. FAU - Woodman, Richard AU - Woodman R AD - School of Medicine, Flinders University, Bedford Park, South Australia, Australia. FAU - Wong, Geoffrey R AU - Wong GR AD - Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia. FAU - Cock, Charles AU - Cock C AD - 1] School of Medicine, Flinders University, Bedford Park, South Australia, Australia [2] Department of Gastroenterology, Flinders Medical Centre, Bedford Park, South Australia, Australia. FAU - Fraser, Robert Jl AU - Fraser RJ AD - 1] School of Medicine, Flinders University, Bedford Park, South Australia, Australia [2] Department of Gastroenterology, Flinders Medical Centre, Bedford Park, South Australia, Australia. LA - eng PT - Journal Article DEP - 20150326 PL - United States TA - Clin Transl Gastroenterol JT - Clinical and translational gastroenterology JID - 101532142 PMC - PMC4816205 EDAT- 2015/03/27 06:00 MHDA- 2015/03/27 06:01 PMCR- 2015/03/01 CRDT- 2015/03/27 06:00 PHST- 2015/01/14 00:00 [received] PHST- 2015/02/23 00:00 [accepted] PHST- 2015/03/27 06:00 [entrez] PHST- 2015/03/27 06:00 [pubmed] PHST- 2015/03/27 06:01 [medline] PHST- 2015/03/01 00:00 [pmc-release] AID - ctg20159 [pii] AID - 10.1038/ctg.2015.9 [doi] PST - epublish SO - Clin Transl Gastroenterol. 2015 Mar 26;6(3):e82. doi: 10.1038/ctg.2015.9.